VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay

VIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.

The following are a few key pieces from VIVUS conference call:

• 3,504 patients are on Qsymia to date;
  
• Average price for 1-month supply is $160, with 20 percent reimbursement coverage since launch; and
  
• About 30 percent of Qsymia prescriptions are abandoned due to cash outlay.

VIVUS is now down 10 percent, after being up 4 percent or so immediately following third-quarter results. For more, click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• Vivakor posts positive operating income as Q2 revenue rises 10%